NLRP3 and Arrhythmia: The MCC950-mediated reduction in VA incidence in the RVOTs of the experimental group suggests that inhibiting NLRP3 with MCC950 reduces the risk of arrhythmia by suppressing arrhythmogenesis in the RVOT.